NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Sunday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 2.2 %

NASDAQ:NURO opened at $4.10 on Friday. The company has a market capitalization of $8.32 million, a P/E ratio of -0.74 and a beta of 2.29. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.70. The firm has a fifty day simple moving average of $4.02 and a 200-day simple moving average of $3.88.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. The firm had revenue of $0.77 million for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.